



U.S. FOOD & DRUG
ADMINISTRATION

Memorandum

DATE April 27, 2023

FROM Triet M. Tran, PharmD, Consumer Safety Officer
Bioresearch Monitoring Branch (BMB)
Division of Inspections and Surveillance (DIS)
Office of Compliance and Biologics Quality (OCBQ)
Telephone: 240-425-3201

THROUGH Dennis T. Cato, Chief BMB

THROUGH Carrie Mampilly, MPH, Director DIS

TO Anna Kwilas, PhD, Chair, STN 125774/0
Ning Hu, MD, Clinical Reviewer
Rommel Maglalang, RPM

SUBJECT Bioresearch Monitoring Final Review Memo
SPONSOR Krystal Biotech, Inc.
PRODUCT VYJUVEK/beremagene geperpavec (B-VEC, also called KB103)
BLA STN 125774/0

Final Summary Statement

Bioresearch Monitoring (BIMO) inspections were issued for three domestic clinical investigator (CI) sites participating in the conduct of study Protocol B-VEC-03. The inspections did not reveal significant problems impacting the data submitted in support of this Biologics License Application (BLA).

Background

BIMO inspection assignments were issued for all three CI sites that participated in the conduct of study Protocol B-VEC-03. The BLA review committee concurred with the sites selected for inspection. The inspection assignments were issued for the following study protocol:

Protocol B-VEC-03 - *A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B -VEC, previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).*

BIMO CI inspections were conducted in accordance with FDA's Compliance Program (CP) 7348.811, Inspection Program for CI. A total of 31 subjects were enrolled in the study, and the inspected sites enrolled 100% of the study population. The inspection assignment included specific questions related to the study protocol, and information submitted in the BLA was compared to source documents at each inspected site.

The inspections verified the data reported in the BLA, including but not limited to subject eligibility, protocol deviations, study drug administration, primary efficacy endpoint, and adverse events for all subjects enrolled at the inspected clinical sites.

Inspection Outcome

No significant objectionable inspectional findings were observed during the inspection. The table below summarizes the BIMO inspections:

Site ID	Number of subjects randomized	Location	483 Issued	Final Inspection Classification
01	14	M. Peter Marinkovich, MD Redwood City, CA	No	No Action Indicated (NAI)
02	8	Mercedes Gonzalez, MD. Coral Gables, FL	No	NAI
03	9	Shireen V. Guide, MD Rancho Santa Margarita, CA	Yes	Voluntary Action Indicated (VAI)

Noteworthy inspectional findings

The inspections did not reveal substantive issues that impact the data submitted in the BLA.

Sponsor Issues

No significant sponsor issues were noted.

Clinical Investigator Issues

Sites 01 and 02 did not receive a Form FDA 483 at the end of the inspection and both inspections received a final classification of NAI.

A Form FDA 483 was issued to Dr. Shireen V. Guide, MD at site 03. The OBIMO Investigator discovered that the designated unblinded staff did not follow the protocol and pharmacy manual as it relates to ensuring that syringes were labeled in accordance with protocol specific requirements, study medications were not stored at protocol specific temperatures, and one subject's randomization date was documented incorrectly in violation of the protocol.

Financial Disclosure

The CI CP directs the FDA investigators to ask the CI if and when he/she disclosed information about his/her financial interests to the sponsor and/or interests of any sub-investigators, spouses and dependent children, and if and when the information was last updated. The information submitted to the BLA was verified at the inspected sites and no deviations were found.

Administrative follow-up

No administrative follow-up is warranted at this time. Should you have any questions about the contents of this memo or any aspect of BIMO, please contact me at 240-425-3201.

Triet M. Tran, PharmD.
Consumer Safety Officer

Electronic Copies

EDR BLA STN125774/0
Anna Kwilas, PhD, Chair,
Ning Hu, MD, Clinical Reviewer
Rommel Maglalang, RPM
Carrie Mampilly, MPH, Division Director
Dennis T. Cato, Branch Chief
cberbimonotification@fda.hhs.gov,
Chron file
ORA BIMOE Correspondence
ORA BIMOW Correspondence
Dustin R. Abaonza, FDA Investigator
Richard A. Lyght, FDA Investigator
Douglas Fiorentino, FDA Investigator
Ronda R. Loyd Jones, FDA Investigator
Samson O. Oluseye, FDA Investigator